Biropepimut-S - Gliknik

Drug Profile

Biropepimut-S - Gliknik

Alternative Names: GL-0817; MAGE-A3 vaccine

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mayo Clinic; University of Maryland, Baltimore
  • Developer Gliknik; University of Pennsylvania
  • Class Cancer vaccines; Peptides
  • Mechanism of Action Immunostimulants; MAGEA-3-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer; Squamous cell cancer
  • No development reported Multiple myeloma

Most Recent Events

  • 01 Mar 2017 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Second-line therapy or greater, Adjuvant therapy) in USA, Puerto Rico, Hungary, Poland, Spain (IV) (NCT02873819)
  • 16 Aug 2016 Gliknik plans a phase II trial for Squamous cell cancer (Adjuvant therapy, Second-line therapy or greater, Combination therapy) in USA, Czech Republic, Germany, Hungary, Poland, Spain, Serbia and Ukraine (IV) (NCT02873819)
  • 08 Aug 2016 Clinical trials in Squamous cell cancer in USA (IV) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top